A 12-Week, Phase 2 Open-Label, Sequential Dose Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of CRN04894 Treatment in Participants with Congenital Adrenal Hyperplasia
This early-stage research study, called a Phase 2 trial, is investigating a new medication, CRN04894, for individuals living with Congenital Adrenal Hyperplasia (CAH). CAH is a condition that affects the adrenal glands. The main goals of this study are to carefully assess how safe the new treatment is and whether it helps improve the condition. Researchers will also look at how the body processes the medication. Participants will receive different doses of the medication over 12 weeks. The study aims to gather important information that can help develop new and better treatments for CAH in the future. Other common CAH medications like methylprednisolone, prednisolone, fludrocortisone, and hydrocortisone are also involved in the study.
At a glance
What is this study about?
This study is investigating a new treatment called CRN04894 for a condition known as Congenital Adrenal Hyperplasia, or CAH. CAH is a lifelong condition that affects the adrenal glands, which are small glands located on top of your kidneys. They produce important hormones that your body needs to function well. In people with CAH, these glands don't work properly, leading to problems with hormone production.
The main aim of this research is to see if CRN04894 is a safe and effective treatment for CAH. This is a "Phase 2" study, which means it's an early step in developing new medicines. At this stage, researchers are looking closely at how the treatment affects the body, checking for any side effects, and seeing if it helps improve the hormone levels that are usually out of balance in CAH.
Understanding how new treatments like CRN04894 work in the body, and whether they can offer a better way to manage CAH, is incredibly important. The information gained from this study could pave the way for new options that might help people with CAH live healthier lives and better manage their condition.
Key takeaways
- This study is testing a new medication, CRN04894, for Congenital Adrenal Hyperplasia (CAH).
- It's primarily looking at safety and if the treatment helps improve CAH.
- The study involves adults aged 18 and over.
- Participants will take the study drug for 12 weeks, with regular visits and blood tests.
- Other common CAH medications are also part of what researchers are studying.
Who may be eligible?
This study is looking for adults aged 18 years and older. There is no upper age limit, so people of any adult age are welcome to consider taking part.
Both men and women are eligible to participate in this research study, as the condition Congenital Adrenal Hyperplasia can affect anyone, regardless of their sex.
More detailed eligibility criteria would be discussed with a doctor or research team to make sure the study is a good fit for you and that you meet all the health requirements for safe participation.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Do you have Congenital Adrenal Hyperplasia (CAH)?
- Are you able to attend regular clinic visits?
- Are you willing to have blood tests as part of the study?
What does participation involve?
If you decide to take part, you will receive the study medication, CRN04894, over a period of 12 weeks. You will start with a certain dose, and this might be adjusted by the study team as the research progresses, depending on how you're doing. During these 12 weeks, you'll have several visits to the study clinic. At these visits, you'll have blood tests, typically in the morning before 11 AM, to check your hormone levels and monitor how the treatment is affecting you. The doctors will also keep a close eye on any side effects you might experience.
Throughout the study, you'll be regularly assessed to make sure you're safe and that the treatment is either helping or if adjustments are needed. The study also involves following up with you after the 12 weeks of treatment to see how you are doing. The total duration of your active involvement in the study, including follow-up, will be explained in detail by the research team.
Potential risks and benefits
Locations (2)
- —UnverifiedGermany
- —UnverifiedItaly
Common questions
What is Congenital Adrenal Hyperplasia (CAH)?
CAH is a condition where your adrenal glands, which sit above your kidneys, don't make enough of certain hormones your body needs.
What kind of treatment is CRN04894?
CRN04894 is a new medication being tested to see if it can help manage the hormone imbalances in people with CAH.
What does 'Phase 2' mean for this study?
Phase 2 means this is an early stage of testing, focusing on whether the treatment is safe and if it shows promise in treating the condition.
Will I still take my regular CAH medicines?
The study involves looking at CRN04894 alongside common CAH medications like hydrocortisone or prednisolone. The study team will discuss your specific treatment plan.
How long will I be in the study?
The treatment part of the study lasts 12 weeks, but there will be follow-up visits after this, making the total involvement longer.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.